Merck Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Merck has been growing earnings at an average annual rate of 21.7%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 9.8% per year. Merck's return on equity is 19.2%, and it has net margins of 14.3%.
Anahtar bilgiler
21.7%
Kazanç büyüme oranı
21.7%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 20.4% |
| Gelir büyüme oranı | 9.8% |
| Özkaynak getirisi | 19.2% |
| Net Marj | 14.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Merck nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 934,432 | 134,074 | 203,609 | 0 |
| 31 Mar 24 | 949,799 | 155,585 | 203,402 | 0 |
| 31 Dec 23 | 961,434 | 178,240 | 200,988 | 0 |
| 30 Sep 23 | 1,035,913 | 160,481 | 193,730 | 0 |
| 30 Jun 23 | 1,023,241 | 147,802 | 194,846 | 0 |
| 31 Mar 23 | 1,084,164 | 163,535 | 186,562 | 0 |
| 31 Dec 22 | 1,124,600 | 179,838 | 190,288 | 0 |
| 30 Sep 22 | 1,147,548 | 163,618 | 202,445 | 0 |
| 30 Jun 22 | 1,157,128 | 173,520 | 201,562 | 0 |
| 31 Mar 22 | 1,112,601 | 140,958 | 212,123 | 0 |
| 31 Dec 21 | 1,064,395 | 131,661 | 208,265 | 0 |
| 30 Sep 21 | 1,002,110 | 134,624 | 202,942 | 0 |
| 30 Jun 21 | 879,843 | 121,326 | 200,267 | 0 |
| 31 Mar 21 | 746,960 | 90,227 | 187,039 | 0 |
| 31 Dec 20 | 655,847 | 71,902 | 185,489 | 0 |
| 30 Sep 20 | 686,477 | 116,256 | 180,309 | 0 |
| 30 Jun 20 | 710,680 | 104,255 | 186,555 | 0 |
| 31 Mar 20 | 743,720 | 101,692 | 197,113 | 0 |
| 31 Dec 19 | 744,635 | 78,257 | 198,814 | 0 |
| 30 Sep 19 | 649,092 | -1,407 | 205,160 | 0 |
| 30 Jun 19 | 633,302 | 13,257 | 196,327 | 0 |
| 31 Mar 19 | 633,747 | 28,904 | 181,236 | 0 |
| 31 Dec 18 | 611,958 | 37,378 | 168,144 | 0 |
| 30 Sep 18 | 144,570 | -65,656 | 3,343 | 0 |
| 30 Jun 18 | 270,973 | -40,950 | 51,264 | 0 |
| 31 Mar 18 | 407,044 | -16,297 | 100,891 | 0 |
| 31 Dec 17 | 582,002 | 29,455 | 159,209 | 0 |
| 30 Sep 17 | 1,125,749 | 179,358 | 340,180 | 0 |
| 30 Jun 17 | 1,063,319 | 157,481 | 326,635 | 0 |
| 31 Mar 17 | 1,045,176 | 159,314 | 338,090 | 0 |
| 31 Dec 16 | 1,034,807 | 153,843 | 327,604 | 0 |
| 30 Sep 16 | 1,036,484 | 146,492 | 336,765 | 0 |
| 30 Jun 16 | 1,031,758 | 149,614 | 327,199 | 0 |
| 31 Mar 16 | 1,018,683 | 152,613 | 311,670 | 0 |
| 31 Dec 15 | 983,446 | 142,545 | 311,514 | 0 |
| 30 Sep 15 | 976,678 | 155,763 | 302,101 | 0 |
| 30 Jun 15 | 963,813 | 165,213 | 292,755 | 0 |
| 31 Mar 15 | 925,146 | 153,964 | 282,312 | 0 |
| 31 Dec 14 | 863,208 | 151,050 | 264,355 | 0 |
| 30 Sep 14 | 524,829 | 109,157 | 219,076 | 0 |
| 30 Jun 14 | 582,779 | 103,945 | 238,253 | 0 |
| 31 Mar 14 | 657,357 | 112,622 | 248,770 | 0 |
| 31 Dec 13 | 805,746 | 147,136 | 255,291 | 0 |
Kaliteli Kazançlar: MERK has high quality earnings.
Büyüyen Kar Marjı: MERK's current net profit margins (14.3%) are lower than last year (14.4%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MERK's earnings have grown significantly by 21.7% per year over the past 5 years.
Büyüme Hızlandırma: MERK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: MERK had negative earnings growth (-9.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4%).
Özkaynak Getirisi
Yüksek ROE: MERK's Return on Equity (19.2%) is considered low.